ReviewExpert opinion on therapeutic targets2016
Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.
Review in Expert opinion on therapeutic targets, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017.Cancer letters · 2021Trial
- Article
- Tuft cells transdifferentiate to neural-like progenitor cells in the progression of pancreatic cancer.Developmental cell · 2025Article
- Tuft cells transdifferentiate to neural-like progenitor cells in the progression of pancreatic cancer.bioRxiv : the preprint server for biology · 2024Article
- Harnessing endoscopic ultrasound-guided radiofrequency ablation to reshape the pancreatic ductal adenocarcinoma microenvironment and elicit systemic immunomodulation.Exploration of targeted anti-tumor therapy · 2024Review
- Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine.Clinical colorectal cancer · 2023Review
- An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms.Nature communications · 2022Article
- Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome?Cancers · 2021Review
- Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes.Advanced therapeutics · 2021Article
- Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification.Journal of clinical medicine · 2020Review
- PDAC-ANN: an artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression.BMC cancer · 2020Article
- The tumor microenvironment of pancreatic adenocarcinoma and immune checkpoint inhibitor resistance: a perplex relationship.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- Optimal respiratory-gated [EJNMMI research · 2019Article
- Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer.Cancer medicine · 2019Article
- Pancreatic cancer microenvironment: a current dilemma.Clinical and translational medicine · 2019Review
- Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase III trials.Journal of Cancer · 2019Review
- Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.Cancer discovery · 2018Article
- Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?Annals of oncology : official journal of the European Society for Medical Oncology · 2017Review
- Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.Cancer cell · 2017Article
- The role of TGF-β and its crosstalk with RAC1/RAC1b signaling in breast and pancreas carcinoma.Cell communication and signaling : CCS · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionPancreatic adenocarcinoma remains one of the most clinically challenging cancers despite an in-depth characterization of the molecular underpinnings and biology of this disease. Recent whole-genome-wide studies have elucidated the diverse and complex genetic alterations which generate a unique oncogenic signature for an individual pancreatic cancer patient and which may explain diverse disease behavior in a clinical setting. AREAS COVERED: In this review article, we discuss the key oncogenic pathways of pancreatic cancer including RAS-MAPK, PI3KCA and TGF-β signaling, as well as the impact of these pathways on the disease behavior and their potential targetability. The role of tumor suppressors particularly BRCA1 and BRCA2 genes and their role in pancreatic cancer treatment are elaborated upon. We further review recent genomic studies and their impact on future pancreatic cancer treatment. EXPERT OPINION: Targeted therapies inhibiting pro-survival pathways have limited impact on pancreatic cancer outcomes. Activation of pro-apoptotic pathways along with suppression of cancer-stem-related pathways may reverse treatment resistance in pancreatic cancer. While targeted therapy or a 'precision medicine' approach in pancreatic adenocarcinoma remains an elusive challenge for the majority of patients, there is a real sense of optimism that the strides made in understanding the molecular underpinnings of this disease will translate into improved outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.